文献速递神经介入DSA

双层血流导向装置(FRED)治疗颅内动脉瘤的多中心研究:长期临床与血管造影随访结果

Long-term clinical and angiographic follow-up results of the dual-layer flow diverter device (FRED) for the treatment of intracranial aneurysms in a multicenter study.
PubMed 文献 · Neuroradiology · 2021-01-03

本前瞻性多中心研究纳入10个中心2013年3月至2016年6月治疗的136例患者共155个动脉瘤,评估FRED的长期安全性和有效性。随访显示总体稳定闭塞率为91.9%(95%CI 87.5-96.3%),不良事件发生率14%,致残率1.5%,死亡1例与动脉瘤治疗无关。

要点

  • FRED治疗颅内动脉瘤长期随访总体稳定闭塞率91.9%(95%CI 87.5-96.3%),再治疗率2%。
  • 支架内狭窄见于7.6%随访患者,仅1例有症状,24个月后除该例外无新发不良事件。
  • 不良事件发生率14%(95%CI 9-21%),致残率1.5%,死亡1例与治疗无关。

核心结论

  • 对于适合血流导向技术的脑动脉瘤,FRED显示出长期有效性,安全性良好且闭塞率满意。

研究设计与样本

  • 前瞻性多中心研究,纳入10个中心2013年3月至2016年6月连续治疗的136例患者共155个动脉瘤。
  • 22例(16.2%)患者表现为责任动脉瘤破裂,大/巨大动脉瘤占队列的1/3,治疗中辅助弹簧圈使用率15.5%。
  • 有效性指标为随访时动脉瘤稳定闭塞的百分比,血管影像随访至少一次者131/136例(96.3%)、148/155个动脉瘤(95.5%),随访最长至75个月(平均37.3个月,中位36个月)。
  • 102/155个动脉瘤(65.8%)在90/136例患者(66.2%)中完成≥24个月随访对照。

诊断标准与关键数值

  • 按最近一次随访对照,总体稳定闭塞率为91.9%(95%CI 87.5-96.3%)。
  • 148个有随访的动脉瘤中3个接受再治疗(2%,95%CI 0.0-4.3%)。
  • 不良事件见于19/136例患者(14%,95%CI 9-21%),致残率1.5%(95%CI 0.0-3.5%)。
  • 死亡率1/136(0.7%,95%CI 0.02-2.2%),与动脉瘤治疗无关。
  • 支架内狭窄(ISS)检出于10/131例有随访的患者(7.6%,95%CI 3.1-12.2%),仅1例有症状。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Our aim was to determine the long-term safety and efficacy of the Flow Re-Direction Endoluminal Device (FRED) in this multicenter study with prospective design.

MATERIALS-METHOD: This study included 136 consecutive patients with 155 aneurysms treated between March 2013 and June 2016 in 10 centers. Twenty-two (16.2%) patients presented with rupture of the index aneurysm. Large/giant aneurysms comprised 1/3 of the cohort. Adjuvant coil use during the treatment was 15.5%. The effectiveness measure in the study was the percentage of aneurysms with stable occlusion at follow-up.

RESULTS: Vascular imaging follow-up was performed at least once in 131/136 (96.3%) patients with 148/155 (95.5%) aneurysms up to 75 months (mean: 37.3 months; median: 36 months according to latest follow-up), and 102/155(65.8%) aneurysms in 90/136 (66.2%) patients had ≥ 24-month control. According to the latest controls, the overall stable occlusion rate was 91.9% (95% CI, 87.5 to 96.3%). Three out of 148 aneurysms with follow-up were retreated (2%, 95% CI 0.0 to 4.3%). Adverse events were noted in 19/136 (14%, 95% CI, 9 to 21%) patients with a morbidity of 1.5% (95% CI, 0.0 to 3.5%). Mortality was 1/136 (0.7%, 95% CI, 0.02 to 2.2%) and was unrelated to aneurysm treatment. In-stent stenosis (ISS) was detected in 10/131 of the patients with follow-up (7.6%, 95% CI; 3.1 to 12.2%), only one being symptomatic. No adverse events have occurred in any of the patients with follow-up after 24 months, except the one resulting from ISS.

CONCLUSION: In the treatment of cerebral aneurysms which were candidates for flow diversion technique, this study showed long-term efficacy of FRED with good safety and occlusion rates.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Dinc H, Saatci I, Oguz S, et al. Long-term clinical and angiographic follow-up results of the dual-layer flow diverter device (FRED) for the treatment of intracranial aneurysms in a multicenter study. Neuroradiology. 2021. PMID: 33392735. doi:10.1007/s00234-020-02627-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。